Amplimune® Receives Regulatory Approval in New Zealand
NovaVive's immunotherapy for calf scours - Amplimune® - has received approval for sale in New Zealand by Agricultural Compounds and Veterinary Medicines (ACVM). NovaVive has appointed Agilis Vet Ltd as its NZ distributor.
NovaVive Seeking to Enhance Quality of Life of Dogs with Cancer
Immunocidin is being evaluated in a clinical study as a palliative therapy for dogs with malignant cancer. The goal is to increase the dogs' comfort and maintain or improve the quality and duration of their remaining life.
Results from a Study with Immunocidin® Equine for Sarcoid Tumors Being Published in the Journal of Equine Veterinary Science
An Iowa State University study concluded that Immunocidin Equine was effective in 52.9% of the cases enrolled (that had a known outcome) after 2-5 injections. The treatment was deemed safe, with swelling the only side effect.
Positive Effect of Settle® on Postpartum Involution Published in the Journal of Equine Veterinary Science
Data from a study with Settle® has been published in the Journal of Equine Veterinary Science. The data show a positive effect of Settle on postpartum uterine involution in the mare, particularly with a two-dose regimen.
Researchers Present Settle® Data to International Veterinary Scientists in Germany
Data from a University of Kentucky study assessing the effect of Settle on histological involution, cell-mediated immunity of the uterus, and clinical endpoints associated with involution was presented in Germany today.
Immunocidin® with Chemotherapy Extends Survival Time in Study with Canine Lymphoma and Osteosarcoma Patients
Positive data from a retrospective study using Immunocidin® with chemotherapy in dogs with Lymphoma and Osteosarcoma were presented at the Veterinary Cancer Society Annual Conference by Dr. Jeannette Kelly, vet oncologist.